GSK press releases Follow GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older RSV affects over six million people aged 60 and older in China each year https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-in-china-for-adults-aged-60-years-and-older/ gsk.com
